{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-269869","form_type":"8-K","ticker":"HOWL","cik":"0001785530","company_name":"Werewolf Therapeutics, Inc.","filed_at":"2023-11-03T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.435485+00:00","generated_at":"2026-06-08T22:39:55.657386+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Werewolf announces preliminary Phase 1/1b data for WTX-124 showing proof of mechanism and early antitumor activity","bullets":["16 heavily pretreated patients in first four monotherapy dose cohorts (1-12 mg); no dose-limiting toxicities or VLS observed.","Two unconfirmed partial responses at 12 mg; one additional patient with evidence of antitumor activity.","CD8+ T and NK cell proliferation/activation in tumor microenvironment seen at 6 mg and 12 mg.","Dose escalation ongoing; cohort 5 (18 mg) fully enrolled; RDE and expansion arms expected H1 2024.","WTX-124 generally well-tolerated in outpatient setting with all TEAEs Grade 1-2."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-269869","json":"https://secwatch.observer/filing/0001193125-23-269869.json","markdown":"https://secwatch.observer/filing/0001193125-23-269869.md","text":"https://secwatch.observer/filing/0001193125-23-269869.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1785530/000119312523269869/0001193125-23-269869-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1785530/000119312523269869/d503964d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T22:39:55.657386+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}